Elevance Health (NYSE:ELV) just dropped its Q4 earnings, and it's a mixed bag. Revenue climbed 6% to $45 billion, fueled by higher premium yields and a 19% surge in its Carelon division.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback